EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Deep Learning-Based Synthetic Contrast-Enhanced Breast MRI for Monitoring Response to Neoadjuvant Therapy

Suleeporn Sujichantararat iD, Debosmita Biswas iD, Anum S Kazerouni iD, Edric D Tsang, Aditi Sathe, Daniel S Hippe, Vivian Y Park iD, Maggie Chung, Jennifer M Specht iD, Suzanne M Dintzis iD, Habib Rahbar, James H Holmes iD und 2 weitere

Cancers · 04.06.2026 · 18 (11) · 1835

DOI: 10.3390/cancers18111835 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 04.06.2026. Verfasst von Suleeporn Sujichantararat und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, University of Washington, Seattle, WA 98195, USA. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIH/NCI, Radiological Society of North America.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Contrast-enhanced (CE) breast MRI is highly sensitive for evaluating breast cancer extent and response to neoadjuvant therapy (NAT) but requires intravenous administration of gadolinium-based contrast agents (GBCA), increasing cost, time, patient discomfort, and health concerns. This study explored the feasibility of reducing GBCA use in treatment monitoring using a deep learning (DL) model to synthesize CE-MRI from non-contrast MRI.

Methods

This IRB-approved retrospective pilot study evaluated women with breast cancer enrolled in an ongoing trial using serial MRI to monitor NAT prior to surgery. A pre-trained DL model was used to synthesize CE-MRI from T1-, T2-, and diffusion-weighted MRI. Changes in tumor volume at early (post-1-cycle NAT) and mid-treatment were measured on synthetic and acquired CE-MRI. Performance for predicting residual cancer burden (RCB) class 0/1 was evaluated using AUC and compared with DeLong’s test.

Results

27 women were included in the study (median age, 47 years [range = 28–75]); 14 (52%) achieved RCB class 0 and six (22%) achieved class 1. Synthetic CE-MRI-derived tumor volumes showed strong correlation with those from acquired CE-MRI at pre-treatment (ρ = 0.92, p < 0.001) and early treatment (ρ = 0.83, p < 0.001), but lower agreement at mid-treatment (ρ = 0.57, p = 0.002). Change in tumor volume on synthetic CE-MRI was numerically similar to acquired CE-MRI for predicting RCB class 0/1 vs. 2/3 at both early (AUC = 0.84 vs. 0.86, p = 0.83) and mid-treatment (AUC = 0.73 vs. 0.75, p = 0.80).

Conclusions

Synthetic CE-MRI demonstrates preliminary feasibility as a non-contrast surrogate for predicting favorable outcomes (RCB class 0/1) in this pilot study, but inconsistencies in tumor volume measurement vs. acquired CE-MRI warrant further model refinement and validation.

Schlagwörter

Stichwörter der Autor:innen

MRIbreastcancergadoliniumneoadjuvant therapy (NAT)pathologic complete response (pCR)residual cancer burden (RCB)synthetic contrast-enhanced MRI modelingtreatment response

Autor:innen und Institutionen

  • Department of Radiology, University of Washington, Seattle, WA 98195, USA.
  • Department of Bioengineering, University of Washington, Seattle, WA 98195, USA.
  • Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
  • Department of Radiology and Research Institute of Radiological Science, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
  • Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA 94143, USA.
  • Division of Hematology and Oncology, University of Washington, Seattle, WA 98195, USA.

ORCID-Profile: Suleeporn Sujichantararat, Debosmita Biswas, Anum S Kazerouni, Vivian Y Park, Jennifer M Specht, Suzanne M Dintzis, James H Holmes, Savannah C Partridge

Förderung

  • NIH HHS
  • NIH/NCI
  • Radiological Society of North America
  • Corewell Health Radiation Oncology MR Research Fund
  • Microsoft AI for Good Lab.

Zitieren

APA

Sujichantararat, S., Biswas, D., Kazerouni, A. S., Tsang, E. D., Sathe, A., Hippe, D. S., Park, V. Y., Chung, M., Specht, J. M., Dintzis, S. M., Rahbar, H., Holmes, J. H., Huang, W., & Partridge, S. C. (2026). Deep Learning-Based Synthetic Contrast-Enhanced Breast MRI for Monitoring Response to Neoadjuvant Therapy. Cancers, 18(11), 1835. https://doi.org/10.3390/cancers18111835

Vancouver

Sujichantararat S, Biswas D, Kazerouni AS, Tsang ED, Sathe A, Hippe DS, et al. Deep Learning-Based Synthetic Contrast-Enhanced Breast MRI for Monitoring Response to Neoadjuvant Therapy. Cancers. 2026;18(11):1835. doi:10.3390/cancers18111835

BibTeX
@article{Sujichantararat2026,
  author = {Sujichantararat, Suleeporn and Biswas, Debosmita and Kazerouni, Anum S and Tsang, Edric D and Sathe, Aditi and Hippe, Daniel S and Park, Vivian Y and Chung, Maggie and Specht, Jennifer M and Dintzis, Suzanne M and Rahbar, Habib and Holmes, James H and Huang, Wei and Partridge, Savannah C},
  title = {Deep Learning-Based Synthetic Contrast-Enhanced Breast MRI for Monitoring Response to Neoadjuvant Therapy},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {11},
  pages = {1835},
  doi = {10.3390/cancers18111835}
}
Kostenlos starten →